You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
<strong>CROI</strong> 2013 Session 40<br />
i Wednesday, 8:30-9 am; Hall B1<br />
Session 37–Plenary<br />
Incorporating New Drugs into Regimens<br />
that Will Change the TB Treatment Paradigm:<br />
The Magic Mountain Meets Table Mountain<br />
123<br />
Andreas Diacon<br />
Stellenbosch Univ, Tygerberg, Cape Town, South Africa<br />
Objectives: This session is directed to clinicians and scientists<br />
interested in TB and anti-TB drugs. It is assumed that participants<br />
are familiar with the basics of clinical TB and current principles of<br />
TB treatment. At the completion of the session, participants will be<br />
informed about novel anti-TB drugs and regimens, the methods used<br />
to explore them, and how they might best be deployed to transform<br />
treatment of drug-susceptible and drug-resistant TB.<br />
j Wednesday, 9-9:30 am; Hall B1<br />
Session 38–Plenary<br />
Treatment with Gene-modified Hematopoietic<br />
Stem Cells May Definitively Abolish HIV-1 Infection<br />
124<br />
Marina Cavazzana-Calvo<br />
U768 INSERM;; AP-HP, Hosp Univ Necker-Enfants Malades;;<br />
Univ Paris Descartes, Sorbonne Paris Cite, IMAGINE Inst;; CIC<br />
Biotherapie GHU Ouest, INSERM-APHP, Paris, France<br />
Objectives: This session is directed to clinicians and scientists<br />
interested in new genetic approaches for HIV-1 infections able to<br />
eliminate the need for indefinite treatment of infected patients. It<br />
is assumed participants are familiar with the human hematopoietic<br />
stem cell system as well as with the biological tools able to introduce<br />
de novo gene functions into these cells or alternatively to disrupt<br />
cellular genes to confer to the hematopoietic compartment a stable<br />
resistance to HIV. At the completion of the session, participants will<br />
be knowledgeable about the first clinical results obtained in this fastmoving<br />
field.<br />
k Wednesday, 10-11:45 am; B402<br />
Session 39–Oral Abstracts<br />
New Discoveries in Vaccines and Gene Therapy<br />
Moderators:<br />
Richard Koup, Vaccine Res Ctr, NIAID, NIH, Bethesda, MD, US<br />
Alexandra Trkola, Univ of Zurich, Switzerland<br />
10:00 125 Dendritic Cells Transduced with Vpx-packaged<br />
LV Vector Encoding CD40L Enhance Cytotoxic<br />
T Cell Responses and Disrupt HIV-1 Latency<br />
Thomas Norton*, E Miller, N Bhardwaj, and N Landau<br />
New York Univ Sch of Med, NY, US<br />
10:15 126 Central Memory T Cell Is the Critical<br />
Component for Sustained CD4 Reconstitution<br />
in HIV Subjects Receiving ZFN CCR5 Modified<br />
CD4 T Cells (SB-728-T)<br />
J Zeidan1 , G Lee2 , J Lalezari3 , R Mitsuyasu4 , S Wang2 , M Giedlin2 ,<br />
G Nichol2 , W Tang2 , <br />
* 1 , and D Ando2 1Vector and Gene Therapy Inst of Florida, Port St Lucie, US;;<br />
2 3 Sangamo BioSci, Richmond, CA, US;; Quest Clin Res, San<br />
Francisco, CA, US;; and 4Univ of California, Los Angeles, US<br />
10:30 127 Protection of Stem Cells Results in Enhanced<br />
Virus-specific Immunity with Recovery of<br />
Unprotected CD4 + T Cells in a Primate AIDS<br />
Model<br />
Patrick Younan* 1 , P Polacino 2,3 , J Kowalski 1 , C Peterson 1 ,<br />
N Maurice 1 , N Williams 1 , G Trobridge 1 , D Von Laer 4 , S-L Hu 2,3 ,<br />
and H-P Kiem 1,2<br />
1 Fred Hutchinson Cancer Res Ctr, Seattle, WA, US;; 2 Univ of<br />
Washington, Seattle, US;; 3 Washington Natl Primate Res Ctr, Seattle,<br />
US;; and 4 Innsbruck Med Univ, Austria<br />
10:45 128 Levels of CD4 + CCR5 + Target T Cells in Rectal<br />
Mucosa Predict Risk of SIV Acquisition and<br />
Replication in Rhesus Macaques Vaccinated<br />
with SIV Gag/Tat Vectors<br />
Diane Carnathan* 1 , K Sheehan 2 , J Yu 1 , D Weiner 2 , H Ertl 3 ,<br />
and G Silvestri 1<br />
1 Yerkes Natl Primate Res Ctr, Emory Univ, Atlanta, GA, US;;<br />
2 Univ of Pennsylvania, Philadelphia, US;; and 3 The Wistar Inst,<br />
Philadelphia, PA, US<br />
11:00 129 T Cells Edited to Express CCR5 or CXCR4<br />
Fused to the C34 Peptide from gp41 Heptad<br />
Repeat-2 Exhibit Robust Protection from<br />
Diverse HIV-1 Isolates<br />
George Leslie* 1 , J Wang 2 , B Haggarty 1 , A Jordan 1 , J Romano 1 ,<br />
K Hua 2 , M Holmes 2 , and J Hoxie 1<br />
1 Univ of Pennsylvania, Philadelphia, US and 2 Sangamo BioSci Inc,<br />
Richmond, CA, US<br />
11:15 130 Poor Neutralizing Antibody Response Is<br />
Associated with Subsequent HIV-1<br />
Superinfection<br />
Gabriel Wagner* 1 , L Hepler 1 , G Caballero 2 , P Phung 3 , S Little 1 ,<br />
S Kosakovsky Pond 1 , D Richman 1,2 , and D Smith 1,2<br />
1 Univ of California, San Diego, La Jolla, US;; 2 VA Hlthcare<br />
System, San Diego, CA, US;; and 3 Monogram Biosci Inc, South San<br />
Francisco, CA, US<br />
11:30 131LB Antibody-induced Perturbation of HIV-1 Env<br />
Structure Is a Quantifiable Parameter that<br />
Modulates the Inhibitory Potency of Antibodies<br />
Hillel Haim* 1,2 , I Salas 1 , and J Sodroski 1,3,4<br />
1 DanaFarber Cancer Inst, Harvard Med Sch, Boston, MA, US;;<br />
2 Carver Coll of Med, Univ of Iowa, Iowa City, US;; 3 Harvard Sch<br />
of Publ Hlth, Boston, MA, US;; and 4 Ragon Inst of MGH, MIT and<br />
Harvard, Boston, MA, US<br />
k Wednesday, 10 am-12 n; B406<br />
Session 40–Oral Abstracts<br />
Virology: From the Outside In<br />
Moderators:<br />
Anna Aldovini, Children’s Hosp Boston, Harvard Univ, MA, US (invited)<br />
James Hoxie, Univ of Pennsylvania, Philadelphia, US<br />
10:00 132 Transmitted/Founder HIV-1 Virions Exhibit<br />
High Env Content, Efficient Dendritic Cell<br />
Binding, Enhanced Infectivity, and Resistance<br />
to Alpha Interferon<br />
N Parrish 1 , E Giorgi 2 , C Wilen 1 , S Iyer 1 , J Kappes 3 , F Gao 4 ,<br />
B Haynes 4 , B Korber 2 , G Shaw 1 , and Beatrice Hahn* 1<br />
1 Univ of Pennsylvania Perelman Sch of Med, Philadelphia, US;; 2 Los<br />
Alamos Natl Lab, NM, US;; 3 Univ of Alabama at Birmingham, US;;<br />
and 4 Duke Univ Sch of Med, Durham, NC, US<br />
10:15 133 Proteolytic Processing of the HIV Envelope<br />
Glycoprotein Precursor Decreases<br />
Conformational Flexibility<br />
Hillel Haim* 1,2 , I Salas 1 , and J Sodroski 1,3,4<br />
1 DanaFarber Cancer Inst, Boston, MA, US;; 2 Carver Coll of Med, Univ<br />
of Iowa, Iowa City, US;; 3 Harvard Sch of Publ Hlth, Boston, MA, US;;<br />
and 4 Ragon Inst of MGH, MIT, and Harvard, Boston, MA, US<br />
10:30 134 Siglec-1 Is a Novel Dendritic Cell Receptor<br />
that Mediates HIV-1 Trans-infection Through<br />
Recognition of Viral Membrane Gangliosides<br />
Nuria Izquierdo-Useros* 1 , M Lorizate 2 , M Puertas 1 ,<br />
M Rodriguez-Plata 1 , N Zangger 3 , M Pino 1 , I Erkizia 1 , A Telenti 3 ,<br />
H-G Krausslich 2 , and J Martinez-Picado 1,4<br />
1 AIDS Res Inst IrsiCaixa, Spain;; 2 Univ Heidelberg, Germany;; 3 Univ<br />
Hosp Ctr and Univ of Lausanne, Switzerland;; and 4 Inst Catalana de<br />
Recerca i Estudis Avancats, Spain<br />
10:45 135 Inhibition of HIV-1 Vif Function by AML Factor<br />
CBF-SMMHC Fusion Proteins<br />
Ke Zhao* 1 , J Du 1 , P Li 1 , Y Rui 1 , M Yan 1 , W Zhang 1 , X-F Yu 1,2 ,<br />
and G Wang 1<br />
1 Inst of Virology and AIDS Res, First Hosp of Jilin Univ,<br />
Changchun, China and 2 Johns Hopkins Univ Bloomberg Sch of Publ<br />
Hlth, Baltimore, MD, US<br />
11:00 136 Crystal Structure of HIV-1 Nef in Complex<br />
with the Hck SH3-SH2 Region Reveals New<br />
Intermolecular Interactions with Functional<br />
Implications<br />
John Jeff Alvarado*, S Tarafdar, T Smithgall, and J Yeh<br />
Univ of Pittsburgh, PA, US<br />
<strong>Program</strong> 17<br />
Wednesday<br />
March 6 Oral Sessions
Change language